Soleno Therapeutics to be Acquired by Neurocrine Biosciences for $2.9 Billion in All-Cash Tender Offer

summarizeSummary

Neurocrine Biosciences has initiated a tender offer to acquire Soleno Therapeutics for $53.00 per share in cash, valuing the company at approximately $2.9 billion and representing a significant premium for shareholders.

check_boxKey Events

• Acquisition Agreement Announced

  Neurocrine Biosciences will acquire Soleno Therapeutics via a tender offer, following a definitive merger agreement dated April 5, 2026.

• All-Cash Offer Price

  Soleno shareholders will receive $53.00 per share in cash, representing a 34% premium to the prior closing price.

• Total Transaction Value

  The acquisition is valued at approximately $2.9 billion in equity.

• Strategic Rationale

  Neurocrine aims to strengthen and diversify its portfolio with Soleno's FDA-approved VYKAT XR, a commercial-stage product for Prader-Willi syndrome that generated $190 million in 2025 sales.

auto_awesomeAnalysis

This SC TO-C filing formally announces the commencement of the tender offer process for Neurocrine Biosciences' acquisition of Soleno Therapeutics. The all-cash deal at $53.00 per share, a 34% premium to the prior close, provides a clear and immediate return for Soleno shareholders. The acquisition is strategic for Neurocrine, aiming to diversify its portfolio with Soleno's FDA-approved VYKAT XR, a commercial-stage product for Prader-Willi syndrome, which generated $190 million in 2025 sales. This transaction is a definitive, thesis-altering event for Soleno, leading to its integration into Neurocrine Biosciences. Investors should monitor the tender offer process and regulatory approvals, expected to close within 90 days.